摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-3-甲氧基丙酸甲酯 | 27704-96-7

中文名称
2-溴-3-甲氧基丙酸甲酯
中文别名
二甲基-溴代-3-甲氧基丙酸
英文名称
methyl 2-bromo-3-methoxypropionate
英文别名
methyl 2-bromo-3-methoxypropanoate;2-Brom-3-methoxy-propionsaeure-methylester;α-Brom-β-methoxy-propionsaeuremethylester
2-溴-3-甲氧基丙酸甲酯化学式
CAS
27704-96-7
化学式
C5H9BrO3
mdl
MFCD07784248
分子量
197.029
InChiKey
NVBLRKGCQVZDMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    69°C 11mm
  • 密度:
    1.465±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    F,Xi
  • 安全说明:
    S16
  • 危险类别码:
    R10
  • 危险品运输编号:
    UN 3272
  • 海关编码:
    2918990090
  • 包装等级:
    III
  • 危险类别:
    3
  • 危险性防范说明:
    P210,P233,P240,P241,P242,P243,P261,P264,P271,P280,P303+P361+P353,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P370+P378,P403+P233,P403+P235,P405,P501
  • 危险性描述:
    H225,H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:25c65d13edf01b3e8ce197584802a257
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 2-bromo-3-methoxypropionate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-bromo-3-methoxypropionate
CAS number: 27704-96-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9BrO3
Molecular weight: 197

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    N-取代的氨基酸N'-苄基酰胺:合成,抗惊厥和代谢活性。
    摘要:
    制备了氨基酸酰胺(AAA)并在癫痫发​​作模型中进行了评估。AAA在最大的电击惊厥(MES)测试中显示中等至优秀的活性,而在皮下美曲唑诱发的(scMet)惊厥测试中则没有活性。AAA抗惊厥活性既不受C(2)取代基,也不受末端胺取代度的强烈影响。一项体外代谢研究表明,结构-活性关系模式部分归因于在N末端胺单元发生的代谢过程。
    DOI:
    10.1016/j.bmc.2004.02.043
  • 作为产物:
    描述:
    参考文献:
    名称:
    环丙烷反应与迈克尔加倍反应。
    摘要:
    在非质子介质中将亲核试剂加到溴代丙烯酸烷基酯上可通过双迈克尔加成反应形成环丙烷的立体有规形成。
    DOI:
    10.1016/s0040-4039(00)98438-7
点击查看最新优质反应信息

文献信息

  • HTS-based discovery and optimization of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor
    作者:István Ledneczki、Anita Horváth、Pál Tapolcsányi、János Éles、Katalin Dudás Molnár、István Vágó、András Visegrády、László Kiss、Áron Szigetvári、János Kóti、Balázs Krámos、Sándor Mahó、Patrik Holm、Sándor Kolok、László Fodor、Márta Thán、Diána Kostyalik、Ottilia Balázs、Mónika Vastag、István Greiner、György Lévay、Balázs Lendvai、Zsolt Némethy
    DOI:10.1016/j.ejmech.2021.113560
    日期:2021.10
    HTS campaign of the corporate compound collection resulted in a novel, oxalic acid diamide scaffold of α7 nACh receptor positive allosteric modulators. During the hit expansion, several derivatives, such as 4, 11, 17 demonstrated not only high in vitro potency, but also in vivo efficacy in the mouse place recognition test. The advanced hit molecule 11 was further optimized by the elimination of the
    公司化合物收集的 HTS 活动产生了一种新型的 α7 nACh 受体阳性变构调节剂草酸二酰胺支架。在命中膨胀,几个衍生物,如4,11,17证明不仅高体外效力,而且在体内在小鼠地方识别测试功效。先进的命中分子11通过消除推定的诱变芳香胺结构单元而得到进一步优化,该结构单元产生了一个新的氨基甲基吲哚化合物家族。在化合物55 的情况下发现了最平衡的物理化学和药理学特征。对接研究揭示了一个亚基间结合位点是我们的化合物最可能的。55不仅在东莨菪碱诱导的健忘症(小鼠位置识别测试)中,而且在自然遗忘(大鼠新物体识别测试)中表现出良好的认知增强特征。此外,化合物55在具有高转化价值的认知范式中是活跃的,即在大鼠触摸屏视觉辨别测试中。因此,选择55作为先导化合物进行进一步优化。基于获得的有利结果,本发明的氨基甲基吲哚簇可以通过α7 nAChR的正变构调节为认知增强提供可行的方法。
  • [EN] MACROCYLIC PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE MACROCYCLIQUES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2015150557A1
    公开(公告)日:2015-10-08
    The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    本发明涉及式(I)的取代大环嘧啶衍生物,其中变量的含义如权利要求中所定义。根据本发明的化合物具有EF2K抑制活性,还可能具有Vps34抑制活性。本发明还涉及制备这种新化合物的方法,包含所述化合物作为活性成分的药物组合物,以及将所述化合物用作药物的用途。
  • SUBSTITUTED BENZOXAZOLES
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160108027A1
    公开(公告)日:2016-04-21
    The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.
    本发明涉及取代苯并恶唑及其制备方法,以及它们用于制备治疗和/或预防疾病,特别是心血管疾病,尤其是血栓性或血栓性栓塞疾病的药物的应用。
  • 取代的苯并噁唑
    申请人:拜耳制药股份公司
    公开号:CN105431428A
    公开(公告)日:2016-03-23
    本发明涉及式(I)的取代的苯并噁唑(其中R 1 表示下式的基团)和其制备方法以及它们用于制备如下目的的药物的用途:治疗和/或预防疾病,特别是心血管的病症,优选血栓形成的或血栓栓塞的病症。
  • [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
    申请人:CALICO LIFE SCIENCES LLC
    公开号:WO2019090069A1
    公开(公告)日:2019-05-09
    Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    本文提供了用于调节elF2B、调节综合应激反应(ISR)以及治疗相关疾病、疾病和症状的化合物、组合物和方法。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物